99 related articles for article (PubMed ID: 26466043)
1. EXAMINE: targeting risk and treatment in diabetes.
Hülsmann M; Pacher R; Neuhold S
Lancet; 2015 Oct; 386(10002):1444-5. PubMed ID: 26466043
[No Abstract] [Full Text] [Related]
2. EXAMINE: targeting risk and treatment in diabetes.
Derosa G; Maffioli P
Lancet; 2015 Oct; 386(10002):1443. PubMed ID: 26466042
[No Abstract] [Full Text] [Related]
3. EXAMINE: targeting risk and treatment in diabetes.
Riche DM; Davis C
Lancet; 2015 Oct; 386(10002):1443-4. PubMed ID: 26466041
[No Abstract] [Full Text] [Related]
4. EXAMINE: targeting risk and treatment in diabetes - Authors' reply.
White WB; Kupfer S; Zannad F
Lancet; 2015 Oct; 386(10002):1445. PubMed ID: 26466044
[No Abstract] [Full Text] [Related]
5. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Zannad F; Cannon CP; Cushman WC; Bakris GL; Menon V; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Lam H; White WB;
Lancet; 2015 May; 385(9982):2067-76. PubMed ID: 25765696
[TBL] [Abstract][Full Text] [Related]
6. Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial.
Bergmark BA; Cannon CP; White WB; Jarolim P; Liu Y; Bonaca MP; Zannad F; Morrow DA
Diabetes Obes Metab; 2017 Jul; 19(7):962-969. PubMed ID: 28195387
[TBL] [Abstract][Full Text] [Related]
7. Lessons from SAVOR and EXAMINE: some important answers, but many open questions.
Schernthaner G; Sattar N
J Diabetes Complications; 2014; 28(4):430-3. PubMed ID: 24713467
[No Abstract] [Full Text] [Related]
8. Welcome reassurance about GLP-1 drugs--but they are still young and not fully grown.
Riddle MC
Diabetes Care; 2015 Feb; 38(2):183-5. PubMed ID: 25614687
[No Abstract] [Full Text] [Related]
9. Alogliptin (nesina) for type 2 diabetes.
Med Lett Drugs Ther; 2013 May; 55(1417):41-3. PubMed ID: 23715128
[No Abstract] [Full Text] [Related]
10. New drugs improve glycemic control in type 2 diabetes, but improving heart health remains elusive.
Mitka M
JAMA; 2013 Oct; 310(14):1435-6. PubMed ID: 24104360
[No Abstract] [Full Text] [Related]
11. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
Derosa G; Maffioli P
N Engl J Med; 2016 Mar; 374(11):1095. PubMed ID: 26981947
[No Abstract] [Full Text] [Related]
12. Risk of new-onset heart failure in patients using sitagliptin: a population-based cohort study.
Eurich DT; Weir DL; Simpson SH; Senthilselvan A; McAlister FA
Diabet Med; 2016 May; 33(5):621-30. PubMed ID: 26206341
[TBL] [Abstract][Full Text] [Related]
13. Effects of intensive glycaemic control on ischaemic heart disease.
Tsujimoto T; Yamamoto-Honda R
Lancet; 2015 Mar; 385(9974):1180. PubMed ID: 25845791
[No Abstract] [Full Text] [Related]
14. Glycaemic control, cardiovascular disease, and mortality in type 2 diabetes.
Chiasson JL; Le Lorier J
Lancet; 2014 Nov; 384(9958):1906-7. PubMed ID: 25088436
[No Abstract] [Full Text] [Related]
15. Effects of intensive glycaemic control on ischaemic heart disease - Authors' reply.
Gerstein HC; Miller ME
Lancet; 2015 Mar; 385(9974):1180-1. PubMed ID: 25845790
[No Abstract] [Full Text] [Related]
16. [Cardiovascular safety of incretin-based antidiabetic treatment - results of completed clinical trials].
Jermendy G
Orv Hetil; 2016 Apr; 157(16):603-10. PubMed ID: 27063427
[TBL] [Abstract][Full Text] [Related]
17. Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial.
Shimada YJ; Cannon CP; Liu Y; Wilson C; Kupfer S; Menon V; Cushman WC; Mehta CR; Bakris GL; Zannad F; White WB;
Am Heart J; 2016 May; 175():18-27. PubMed ID: 27179720
[TBL] [Abstract][Full Text] [Related]
18. Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care).
Cavender MA; White WB; Jarolim P; Bakris GL; Cushman WC; Kupfer S; Gao Q; Mehta CR; Zannad F; Cannon CP; Morrow DA
Circulation; 2017 May; 135(20):1911-1921. PubMed ID: 28246236
[TBL] [Abstract][Full Text] [Related]
19. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.
Huang Y; Abdelmoneim AS; Light P; Qiu W; Simpson SH
J Diabetes Complications; 2015 Mar; 29(2):196-202. PubMed ID: 25534984
[TBL] [Abstract][Full Text] [Related]
20. Are users of sulphonylureas at the time of an acute coronary syndrome at risk of poorer outcomes?
Nagendran J; Oudit GY; Bakal JA; Light PE; Dyck JR; McAlister FA
Diabetes Obes Metab; 2013 Nov; 15(11):1022-8. PubMed ID: 23668425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
